HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Olmesartan

HCID 158781
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
144689-24-7
Standard SMILES
CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
InChIKey
VTRAEEWXHOVJFV-UHFFFAOYSA-N
Molecular formula
C24H26N6O3
Average molar mass
446.5 g/mol
Monoisotopic mass
446.20663871

Overview

Olmesartan is a biphenylyltetrazole. It has a role as an antihypertensive agent and an angiotensin receptor antagonist.

Names & identifiers

Preferred name
Olmesartan
IUPAC
5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
English name
Olmesartan
Molecular formula
C24H26N6O3
Molecular weight
446.5

Names & synonyms

Olmesartan144689-24-7RNH-6270omesartanNSC-7598108W1IQP3U10DTXSID2040571CHEBI:484161H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-4-(hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylic acid(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
Show more names
Olmesartan AcidOlMesartan EP IMpurity ACS 088CS-415RNH 6270CS 088-d6OMSTint-HOlmesartan 98%
4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylic acid4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acidolmesartanum4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylic acid4-(2-hydroxypropan-2-yl)-2-propyl-1-((4-(2-(1H-1,2,3,4-tetrazol-5-yl)phenyl)phenyl)methyl)-1H-imidazole-5-carboxylic acidolmesartanum medoxomilumRefChem:55770DTXCID0020571

Properties

Computed structural propertiesFilling in

XLogP
3.2
Topological polar surface area
130 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
7
Rotatable bonds
8
Heavy atoms
33
Formal charge
0
Complexity
656

Experimental & physicochemical properties

Drugs · 3 items

Pharmaceuticals -> Metabolite of Olmesartan medoxonil

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Antihypertensives

LogP5.9
Solubility · 3 items

Insoluble

Soluble to 20 mM in DMSO

1.05e-02 g/L

Human DrugsBreast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Blockers; ARBs
Melting Point175 - 180 °C
Physical DescriptionSolid
Dissociation Constants4.3
Other Experimental PropertiesWhite to light yellowish-powder or crystalline powder. It is practically insoluble in water and sparingly soluble in methanol /Olmesartan medoxomil/

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 33.3% (1 of 3) of reports.

Warning

H302 (66.7%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory InformationREACH registered substance: 4-(Hydroxy-1-methyethyl)-2-propyl-1-[[2′-[1H-tetrazol-5-yl]-1,1′-biphenyl-4-yl]methyl]-1H-imidazole-5-carboxylic acid (EC: 646-413-5)
FDA Requirements · 1 item

The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including olmesartan medoxomil, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Olmesartan medoxomil/

Hazard Classes and CategoriesAcute Tox. 4 (66.7%)

Safety & protection

Storage ConditionsStore at 20-25 °C (68-77 °F)
Disposal Methods · 2 items

SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

Chemistry & industry

Pharmacology

Protein BindingOlmesartan is highly bound to plasma proteins. 99% of the administered dose is found in a bound state with no penetration in red blood cells.
Pharmacodynamics · 1 item

Overall, olmesartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. **Hypotension in Volume- or Salt-Depleted Patients** In patients with an activated renin-angiotensin aldosterone system, such as volume-and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may be anticipated after initiation of treatment with olmesartan. Initiate treatment under close medical supervision. If hypotension does occur, place the patient in the supine position and, if necessary, give an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized. Valvular Stenosis: there is concern on theoretical grounds that patients with aortic stenosis might be at a particular risk of decreased coronary perfusion, because they do not develop as much afterload reduction. **Impaired Renal Function** As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with olmesartan. In patients whose renal function may depend upon the activity of the renin-angiotensin- aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. Similar results may be anticipated in patients treated with olmesartan. In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. There has been no long-term use of olmesartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar results may be expected. **Sprue-like Enteropathy** Severe, chronic diarrhea with substantial weight loss has been reported in patients taking olmesartan months to years after drug initiation. Intestinal biopsies of patients often demonstrated villous atrophy. If a patient develops these symptoms during treatment with olmesartan, exclude other etiologies. Consider discontinuation of olmesartan medoxomil in cases where no other etiology is identified. **Electrolyte Imbalances** Olmesartan medoxomil contains olmesartan, a drug that inhibits the renin-angiotensin system (RAS). Drugs that inhibit the RAS can cause hyperkalemia. Monitor serum electrolytes periodically.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
144689-24-7、144689-63-4
PubChem CID
158781
DTXSID
DTXSID2040571
ChEMBL
CHEMBL1516
ChEBI
CHEBI:48416
UNII
8W1IQP3U10
EC Number
646-413-5
Nikkaji
J715.876I

Physicochemical properties

Melting point
186 · 186-188°C
Boiling point
738.3 · 738.3±70.0 °C(Predicted)
Density
1.33 · 1.33
storage temp.
2 · 2-8°C
solubility
DMSO (Slightly), Methanol (Slightly, Heated)
pka
2.39 · 2.39±0.50(Predicted)
form
powder
color
white to beige
Stability
Hygroscopic
InChIKey
VTRAEEWXHOVJFV-UHFFFAOYSA-N
SMILES
C1(CCC)N(CC2=CC=C(C3=CC=CC=C3C3=NNN=N3)C=C2)C(C(O)=O)=C(C(O)(C)C)N=1
CAS DataBase Reference
144689 · 144689-24-7(CAS DataBase Reference)
FDA UNII
8 W1IQP3U10 · 8W1IQP3U10
UNSPSC Code
12352200 · 12352200
NACRES
77 · NA.77
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H312-H332
Precautionary statements
280 · P280-P302+P352-P312-P322-P363-P501-P261-P271-P304+P340-P312-P264-P270-P301+P312-P330-P501
WGK Germany
3 · WGK 3
RTECS
4014100 · NI4014100
HS Code
29339900 · 29339900
Storage Class
11 · 11 - Combustible Solids
Hazardous Substances Data
144689 · 144689-24-7(Hazardous Substances Data)
REACH Registrations
Active

SRP: At the time of review, regulatory criteria for small quantity disposal are subject to significant revision, however, household quantities of waste pharmaceuticals may be managed as follows: Mix with wet cat litter or coffee grounds, double bag in plastic, discard in trash.

Toxicology

Interactions · 5 items

Do not co-administer aliskiren with Benicar in patients with diabetes. Avoid use of aliskiren with Benicar in patients with renal impairment (GFR <60 mL/min).

Dual Blockade of the renin-angiotensin system (RAS)with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on Benicar and other agents that affect the RAS.

Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists, including Benicar. Monitor serum lithium levels during concomitant use.

Potential pharmacologic interaction (attenuated hypotensive effects) when angiotensin II receptor antagonists are used concomitantly with nonsteroidal anti-inflammatory agents (NSAIAs), including selective cyclooxygenase-2 (COX-2) inhibitors. Possible deterioration of renal function, including possible acute renal failure, in geriatric, volume-depleted (including those receiving concomitant diuretic therapy), or renally impaired patients; renal function should be monitored periodically in patients receiving concomitant therapy with olmesartan and an NSAIA, including selective COX-2 inhibitors.

For more Interactions (Complete) data for Olmesartan (10 total), please visit the HSDB record page.

HepatotoxicityOlmesartan has been associated with a low rate of serum aminotransferase elevations (
Environmental Fate · 3 items

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 1.2X10+4(SRC), determined from a structure estimation method(2), indicates that olmesartan is expected to be immobile in soil(SRC). The estimated pKa values of 4.96 and 5.57(3) indicate that this compound will exist almost entirely in the zwitterion form in the environment. Volatilization from moist soil is not expected because the compound exists as an ion and ions do not volatilize. Olmesartan is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.7X10-21 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2014).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 1.2X10+4(SRC), determined from a structure estimation method(2), indicates that olmesartan is expected to adsorb to suspended solids and sediment(SRC). The estimated pKa values of 4.96 and 5.57(3) indicates olmesartan will exist almost entirely in the ion form at pH values of 5 to 9 and, therefore, volatilization from water surfaces is not expected to be an important fate process(SRC). According to a classification scheme(4), an estimated BCF of 3(SRC), from its estimated log Kow(2)and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data in water were not available(SRC, 2014).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), olmesartan, which has an estimated vapor pressure of 1.7X10-21 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase olmesartan may be removed from the air by wet and dry deposition(SRC). Olmesartan contains chromophores that absorb at wavelengths >290 nm(3) and, therefore, may be susceptible to direct photolysis by sunlight(SRC).

Adverse EffectsARBs are known for their relatively mild side-effect profile compared to other antihypertensive medications. While side effects are not exceptionally common, as with most drugs, olmesartan can produce a constellation of side effects.
Milk ConcentrationsEXPERIMENTAL: Olmesartan is distributed into milk in rats; it is not known whether the drug is distributed into milk in humans.
Toxicity Summary · 2 items

IDENTIFICATION AND USE: Olmesartan is a white to light yellowish-powder or crystalline powder that is formulated into oral tablets. Olmesartan is an angiotensin II type 1 (AT1) receptor antagonist. It is used alone or in combination with other classes of antihypertensive agents (e.g., thiazide diuretics) in the management of hypertension. HUMAN EXPOSURE AND TOXICITY: Limited data are available related to drug overdose in humans. The most likely manifestations of olmesartan overdose include hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurs. While olmesartan can be used in hypertensive children, it is not approved for use in children less one 1 year of age. Drugs that act directly on the renin-angiotensin system (RAS) can have effects on the development of immature kidneys. The use of olmesartan in pregnancy is also contraindicated. While use during the first trimester does not suggest a risk of major anomalies, use during the second and third trimester may cause teratogenicity and severe fetal and neonatal toxicity. Fetal toxic effects may include anuria, oligohydramnios, fetal hypocalvaria, intrauterine growth restriction, premature birth, and patent ductus arteriosus. Anuria-associated anhydramnios/oligohydramnios may produce fetal limb contractures, craniofacial deformation, and pulmonary hypoplasia. Severe anuria and hypotension, resistant to both pressor agents and volume expansion, may occur in the newborn following in utero exposure to olmesartan. ANIMAL STUDIES: Olmesartan was not carcinogenic when administered by dietary administration to rats for up to 2 years. Also, the fertility of male and female rats was unaffected by administration of olmesartan. No teratogenic effects were observed when drug was administered to pregnant rats at oral doses up to 1000 mg/kg/day or pregnant rabbits at oral doses up to 1 mg/kg/day. However, significant decreases in pup birth weight and weight gain were observed in rats. In addition, delays in developmental milestones (delayed separation of ear auricula, eruption of lower incisors, appearance of abdominal hair, descent of testes, and separation of eyelids) and dose-dependent increases in the incidence of dilation of the renal pelvis were observed in rats. Olmesartan tested negative in the in vitro Syrian hamster embryo cell transformation assay and showed no evidence of genetic toxicity in the Ames (bacterial mutagenicity) test. However, the drug was shown to induce chromosomal aberrations in cultured cells in vitro (Chinese hamster lung) and tested positive for thymidine kinase mutations in the in vitro mouse lymphoma assay. Olmesartan tested negative in vivo for mutations in the MutaMouse intestine and kidney and for clastogenicity in mouse bone marrow (micronucleus test) at oral doses of up to 2000 mg/kg.

While data on olmesartan's toxicity is limited, given the mechanism of action, the likely presenting toxic symptoms would include hypotension and tachycardia. The toxicity could also manifest with altered vision, angina, vertigo, lightheadedness, and diaphoresis. These possible toxicities mimic the side effect profile of the medication. While no antidote exists, activated charcoal may be appropriate if the consumption of olmesartan was within four hours of decontamination. Supportive measures include monitoring vital signs every six hours post-consumption to monitor for marked hypotension or hemodynamic instability. The patient should perform leg raising while lying supine to improve venous return to the heart. If severe hypotension persists, vasopressors are a treatment option in extreme circumstances. Another possible cleansing method would include hemodialysis if a patient was remarkably unstable and refractory to vasopressor medication, although rarely necessary. Also, cardiac life support is always indicated if cardiac arrest occurs, and preservation of an airway with an endotracheal tube in situations with a threatened airway.

Soil Adsorption/Mobility · 1 item

Using a structure estimation method based on molecular connectivity indices(1), the Koc of olmesartan can be estimated to be 1.2X10+4(SRC). According to a classification scheme(2), this estimated Koc value suggests that olmesartan is expected to be immobile in soil. The estimated pKa values of 4.96 and 5.57(3) indicate that this compound will exist in the zwitterion form in the environment.

Human Toxicity Excerpts · 5 items

/SIGNS AND SYMPTOMS/ Limited data are available related to overdosage in humans. The most likely manifestations of overdosage would be hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurs.

/SIGNS AND SYMPTOMS/ Recently, a new enteropathy has been described: olmesartan-associated enteropathy. However, the association has been questioned: a phase 3 trial and a cohort study found no association between gastrointestinal events and olmesartan. We collected French cases of sartan-associated enteropathy to describe further this entity, confirm or refute causality, and determine if the association exists with other sartans. French gastroenterologists were invited to report cases of sartan-associated enteropathy and collect clinical, biological and histological data. Patients with diarrhea and histological duodenal abnormalities were included. Thirty-six patients with olmesartan-associated enteropathy were reported, including 32 with villous atrophy and four without. There was only one patient with irbesartan-associated enteropathy. None of the patients died. Patients with villous atrophy had diarrhea, vomiting, renal failure, hypokalemia, body weight loss and hypoalbuminemia. Thirty-one patients were hospitalized; four required intensive care. Anti-transglutaminase and anti-enterocyte antibodies were negative; anti-nuclear antibodies were positive (9/11). Endoscopic duodenal biopsies showed villous atrophy (32/32) and polyclonal intra-epithelial CD3+CD8+ lymphocytosis (11/11). Exactly, 14/15 patients responded to steroids and/or immunosuppressants, prescribed because of suspected autoimmune enteropathy. Ten olmesartan interruptions were followed by reintroductions before steroids or immunosuppressants. Interruptions were followed by remissions (9/10), but reintroductions were followed by relapses (9/9). Twenty-nine patients were in remission since olmesartan interruption, including 26 without immunosuppressants. Patients with normal villi had similar clinical characteristics, but mild histological abnormalities (intra-epithelial lymphocytosis and lamina propria lymphocytic infiltration). Olmesartan causes a severe and immune-mediated enteropathy, with or without villous atrophy. Enteropathy associated with other sartans seems to be very rare.

/CASE REPORTS/ A woman took olmesartan (dose not specified) for hypertension in the last month of pregnancy. Severe oligohydramnios developed and she delivered a 3.045 kg female infant by cesarean section at 36 weeks gestation. Apgar scores were 7 and 7. The infant received dialysis for renal failure but died on day 45. Autopsy revealed severe tubular dysgenesis and the renal arteries and arteriole walls were thickened.

/CASE REPORTS/ We report on a case of fetal toxicity due to maternal treatment with olmesartan medoxomil. At 29 weeks' gestation, oligohydramnios was found, although the fetus had normal kidneys on ultrasound evaluation. Withdrawal of olmesartan medoxomil, maternal rehydration, and a single dose of furosemide reversed the renal impairment. After term delivery, the neonate was confirmed to have normal renal function. The case suggested that fetal renal impairment due to olmesartan medoxomil may be reversible.

Artificial Pollution SourcesOlmesartan's production and use as an antihypertensive(1) may result in its release to the environment through various waste streams(SRC).
Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

olmesartan

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Environmental Bioconcentration · 1 item

An estimated BCF of 3 was calculated in fish for olmesartan(SRC), using an estimated log Kow of 3.63(1) and a regression-derived equation(1). According to a classification scheme(2), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).

Volatilization from Water/Soil · 1 item

The estimated pKa values of 4.96 and 5.57(1) indicate olmesartan will exist almost entirely in the ion form at pH values of 5 to 9 and, therefore, volatilization from water or moist soil surfaces is not expected to be an important fate process(SRC). Olmesartan is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.7X10-21 mm Hg(SRC), determined from a fragment constant method(3).

Regulatory information

FDA Requirements · 1 item

The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including olmesartan medoxomil, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Olmesartan medoxomil/

Safety data

wgk
WGK 3
rtecs
NI4014100
hs_code
29339900
Signal word
Warning
Symbol(GHS)
GHS07
Storage Class
11 - Combustible Solids
Hazard statements
H302-H312-H332
REACH Registrations
Active
Precautionary statements
P280-P302+P352-P312-P322-P363-P501-P261-P271-P304+P340-P312-P264-P270-P301+P312-P330-P501
Hazardous Substances Data
144689-24-7(Hazardous Substances Data)
Mechanism of Action · 3 items

Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects. As the principal pressor agent of the renin-angiotensin system, Angiotensin II causes vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Its action is, therefore, independent of the pathways for angiotensin II synthesis. Overall, olmesartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Olmesartan also effects on the renin-angiotensin aldosterone system (RAAS) plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease, heart failure, and renal disease. In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling.

Angiotensin-converting enzyme 2 (ACE2) is highly expressed in the kidney and converts angiotensin (Ang) II to Ang-(1-7), a renoprotective peptide. Urinary ACE2 has been shown to be elevated in patients with chronic kidney disease. However, the effects of antihypertensive agents on urinary ACE2 remain unclear. METHODS: Of participants in the Tanno-Sobetsu cohort study in 2011 (n = 617), subjects on no medication (n = 101) and hypertensive patients treated with antihypertensive agents, including the calcium channel blockers amlodipine and long-acting nifedipine; the ACE inhibitor enalapril; and the Ang II receptor blockers losartan, candesartan, valsartan, telmisartan, and olmesartan, for more than 1 year (n = 100) were enrolled, and urinary ACE2 level was measured. Glucose and hemoglobin A1c were significantly higher in patients treated with enalapril, telmisartan or olmesartan than in the control subjects. Urinary albumin-to-creatinine ratio (UACR) was significantly higher in patients treated with enalapril than in the control subjects. Urinary ACE2 level was higher in the olmesartan-treated group, but not the other treatment groups, than in the control group. Urinary ACE2 level was positively correlated with systolic blood pressure (r = 0.211; P = 0.003), UACR (r = 0.367; P < 0.001), and estimated salt intake (r = 0.260; P < 0.001). Multivariable regression analysis after adjustment of age, sex, and the correlated indices showed that the use of olmesartan was an independent predictor of urinary ACE2 level. In contrast with other antihypertensive drugs, olmesartan may uniquely increase urinary ACE2 level, which could potentially offer additional renoprotective effects.

Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT receptor in vascular smooth muscle. Its action is, therefore, independent of the pathways for angiotensin II synthesis. An AT receptor is found also in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis. Olmesartan has more than a 12,500-fold greater affinity for the AT receptor than for the AT receptor. Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is a mechanism of many drugs used to treat hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because olmesartan medoxomil does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II levels do not overcome the effect of olmesartan on blood pressure.

Biological Half-Life · 2 items

The mean plasma olmesartan half-life is reported to be from 10-15 hours after multiple oral administration.

Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.

Metabolism/Metabolites · 2 items

Olmesartan medoxomil is rapidly and completely bioactivated by ester hydrolysis to olmesartan during absorption from the gastrointestinal tract. This rapid first-pass metabolism was confirmed by the lack of measurable amounts of olmesartan medoxomil in plasma or excreta. This first-pass metabolism is not driven by cytochrome enzymes and hence it is not expected to interact with other drugs via this mechanism. The pharmacologically active moiety does not appear to undergo further metabolism.

Following the rapid and complete conversion of olmesartan medoxomil to olmesartan during absorption, there is virtually no further metabolism of olmesartan.

FDA Pharmacological Classification · 5 items

8W1IQP3U10

OLMESARTAN

Mechanisms of Action [MoA] - Angiotensin 2 Receptor Antagonists

Established Pharmacologic Class [EPC] - Angiotensin 2 Receptor Blocker

Olmesartan is an Angiotensin 2 Receptor Blocker. The mechanism of action of olmesartan is as an Angiotensin 2 Receptor Antagonist.

MeSH Pharmacological Classification · 2 items

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.

Absorption, Distribution and Excretion · 6 items

When taken orally, the prodrug olmesartan medoxomil is rapidly absorbed in the gastrointestinal tract and metabolized to olmesartan. The esterification with medoxomil was created with the intention of increasing olmesartan bioavailability from 4.5% to 28.6%. Oral administration of 10-160 mg of olmesartan has been shown to reach peak plasma concentration of 0.22-2.1 mg/L after 1-3 hours with an AUC of 1.6-19.9mgh/L. The pharmacokinetic profile of olmesartan has been observed to be nearly linear and dose-dependent under the therapeutic range. The steady-state level of olmesartan is achieved after once a day dosing during 3 to 5 days.

The main elimination route of olmesartan is in the unchanged form through the feces. From the systemically bioavailable dose, about 10-16% is eliminated in the urine.

17 L

Total plasma clearance is 1.3 L/h and the renal clearance is 0.6 L/h.

In rats, olmesartan crossed the blood-brain barrier poorly, if at all. Olmesartan passed across the placental barrier in rats and was distributed to the fetus.

The volume of distribution of olmesartan is approximately 17 L. Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells. The protein binding is constant at plasma olmesartan concentrations well above the range achieved with recommended doses.

Cellular LocationsMembrane
Metabolite PathwaysOlmesartan Action Pathway

Uses & manufacturing

Uses · 2 items

MEDICATION

Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents

Methods of ManufacturingPreparation: H. Yanagisawa et al., European Patent Office patent 503785; eidem, United States of America patent 5616599 (1992, 1997 both to Sankyo).
Formulations/Preparations · 3 items

Table: Olmesartan Medoxomil Preparations [Table#8198]

Table: Olmesartan Medoxomil Combination Preparations [Table#8199]

Oral: 5 mg, 20 mg and 40 mg tablets (Olmetec). /Olmesartan medoxomil/

Applications · 5 items

UsesAn labelled angiotensin II receptor antagonist. Used as an anti-hypertensive

UsesAngiotensin II inhibitor, antihypertensive

UsesAn angiotensin II (AT1) receptor antagonist

UsesOlmesartan Acid (Olmesartan EP Impurity A) is an angiotensin II receptor antagonist. Used as an anti-hypertensive.

General DescriptionOlmesartan medoxomil, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl-5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate (Benicar, Olmetec) uses the tetrazolering system as its acidic system, which participates inreceptor binding.When administered to a patient, the drugis rapidly and completely bioactivated by ester hydrolysis ofthe medoxomil during absorption from the gastrointestinaltract. Once the prodrug is converted to the active form, virtuallyno further metabolism occurs. In September 2007, theFood and Drug Administration (FDA) approved its use as acombination product with the calcium channel blocker amlodipinefor the management of hypertension. This combinationproduct is sold under the tradename of Azor.

Additional notes

DefinitionChEBI: Olmesartan is a biphenylyltetrazole. It has a role as an antihypertensive agent and an angiotensin receptor antagonist.

For more Human Toxicity Excerpts (Complete) data for Olmesartan (10 total), please visit the HSDB record page.